Meeting Banner
Abstract #1686

An Optimized Dual-targeted Anti-angiogenic Therapy Strategy with Regorafenib and Imatinib for Colorectal Cancer by Multi-parametric MRI

Lingtao Zhang1, Wenfeng Mai1, Dong Zhang1, and Changzheng Shi1
1the First Affiliated Hospital of Jinan University, Guangzhou, China

Synopsis

Keywords: Quantitative Imaging, Quantitative Imaging

Motivation: Regorafenib’s limited duration and resistance in CRC treatment necessitate strategies for enhanced efficacy.

Goal(s): To evaluate whether alternating regorafenib with imatinib can improve therapeutic outcomes in CRC.

Approach: This study used mpMRI to monitor tumor microenvironment changes in CRC models receiving alternating regorafenib/imatinib, focusing on perfusion, hypoxia, and cellular responses.

Results: Alternating therapy achieved superior tumor perfusion, sustained hypoxia reduction, and enhanced apoptosis, suggesting potential for improved patient survival and quality of life.

Impact: This study demonstrates that alternating regorafenib and imatinib therapy enhances tumor response, prolongs antitumor effects, and overcomes treatment resistance, improving survival outcomes in CRC.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.

Keywords